Hanmi’s 3-sbustance combination drug containing Amosartan & rosuvastatin represented at EHS

Published: 2017-06-22 16:26:00
Updated: 2017-06-22 09:53:04

2 case results of clinical trial for ‘Amosartan,’ a combination drug developed by Hanmi Pharm, were announced at the European Society of Hypertension(ESH).

Hanmi Pharm announced on the 20th that it presented a Phase 3 clinical trial result of the 3-substance combination drug containing the Amosa...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.